Survival outcomes of adjuvant therapy in resected stage III melanoma: results from a real-life cohort study (TAMARIS)
- 25 June 2026
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 244, 116878
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Long-Term Follow-Up of Real-World Adjuvant Anti–PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaJournal of Clinical Oncology, 2025
- Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaNew England Journal of Medicine, 2024
- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III MelanomaNew England Journal of Medicine, 2024
- Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapiesCancer Medicine, 2024
- Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based studyJNCI: Journal of the National Cancer Institute, 2023
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238Clinical Cancer Research, 2023
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaNew England Journal of Medicine, 2023
- Real‐world outcomes using PD‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and SwitzerlandJournal of the European Academy of Dermatology and Venereology, 2022
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaNew England Journal of Medicine, 2018
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine, 2017